MitoQ® Launches Advanced Third Generation CoQ Antioxidant Dietary Supplement

NEW YORK, Dec. 3, 2013 /PRNewswire/ -- MitoQ® Limited is excited to announce the release of their newest offering, MitoQ® Targeted Antioxidant Dietary Supplement. Published studies show that the supplement, which delivers the well known antioxidant CoQ to the mitochondria (our cellular power source) better than ever before, helps repair mitochondrial dysfunction, significantly reduces oxidative damage to cells and by association supports heart, liver and brain health while assisting in the increase of energy, libido and healthy aging. This will be the second launch from the brand, which released an anti-aging Moisturizing Serum to the U.S. market earlier this year.

MitoQ Targeted Antioxidant Dietary Supplement will be available globally on December 3^rd at MitoQ.com. The patented CoQ delivery technology the brand is recognized for, the MitoQ® molecule, will continue to be the key active ingredient in this new product offering.  MitoQ Targeted Antioxidant Dietary Supplement targets and protect mitochondria, the cellular power plant, to reverse and prevent oxidative damage to support mitochondrial health, energy and healthy aging.

"We are thrilled to finally be sharing this groundbreaking supplement with the world after over a decade of development and testing," said Greg Macpherson, CEO of MitoQ® Limited. "We started with the MitoQ® Anti-aging Serum so that people could physically see the power of this amazing molecule and the effects it can have on their skin, and now they will be able to benefit from it working within, promoting overall wellness."

The MitoQ® molecule is the brainchild of Dr. Michael Murphy of Cambridge and Professor Rob Smith of Otago University, New Zealand, who were studying the correlation of mitochondria, oxidative stress and diseases. In a cutting-edge development a unique electrostatic penetration system was devised to deliver the CoQ antioxidant to the cell's mitochondria, neutralizing free radicals where they are produced, slowing the cell aging process and supporting the repair of prior damage. The MitoQ molecule has been the subject of over a decade and 30 million dollars of research and development, has global patents and has been featured in over 180 papers published in medical research journals around the world.

About MitoQ Limited:
Founded in 2005, MitoQ Limited is a New Zealand health company that holds licenses to commercialise a pipeline of globally patented mitochondrial targeted compounds.

Mitochondrial dysfunction is now known to be involved in over 200 diseases and conditions and has become an intense area of interest as a target to improve human health.

SOURCE MitoQ Limited